Cargando…

Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells

The commonly used antimitotic chemotherapeutic agents such as taxol and vinblastine arrest cell cycle progression by disrupting mitotic spindles, and cause cancer cells to undergo apoptosis through ‘mitotic catastrophe’. The molecular mechanisms by which these drugs induce apoptosis and their releva...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Chen, Wang, Xin, Shen, Zhirong, Chen, She, Yu, Hong, Williams, Noelle, Wang, Gelin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951888/
https://www.ncbi.nlm.nih.gov/pubmed/29497138
http://dx.doi.org/10.1038/s41422-018-0018-6
_version_ 1783323090389827584
author Qi, Chen
Wang, Xin
Shen, Zhirong
Chen, She
Yu, Hong
Williams, Noelle
Wang, Gelin
author_facet Qi, Chen
Wang, Xin
Shen, Zhirong
Chen, She
Yu, Hong
Williams, Noelle
Wang, Gelin
author_sort Qi, Chen
collection PubMed
description The commonly used antimitotic chemotherapeutic agents such as taxol and vinblastine arrest cell cycle progression by disrupting mitotic spindles, and cause cancer cells to undergo apoptosis through ‘mitotic catastrophe’. The molecular mechanisms by which these drugs induce apoptosis and their relevance to clinical efficacy are not known. Facilitated by a new spindle poison diazonamide, we found that apoptosis induced by these agents requires death receptor 3 (DR3). Mitotic arrest by these agents induces lysosome-dependent secretion of the DR3 ligand, TL1A. Engagement of TL1A with DR3 stimulates the formation of FADD-containing and caspase-8-containing death-inducing signaling complex (DISC), which subsequently activates apoptosis in cells that express DR3. Expression of DR3 and TL1A correlates with the apoptotic response of human tumor xenograft models and human cancer cell lines to antimitotic drugs, providing further evidence that these drugs kill cancer cells through the DR3/TL1A-mediated pathway. These results suggest that TL1A and DR3 may hold promise to be used as biomarkers for predicting clinical response to antimitotic therapeutics.
format Online
Article
Text
id pubmed-5951888
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59518882018-05-29 Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells Qi, Chen Wang, Xin Shen, Zhirong Chen, She Yu, Hong Williams, Noelle Wang, Gelin Cell Res Article The commonly used antimitotic chemotherapeutic agents such as taxol and vinblastine arrest cell cycle progression by disrupting mitotic spindles, and cause cancer cells to undergo apoptosis through ‘mitotic catastrophe’. The molecular mechanisms by which these drugs induce apoptosis and their relevance to clinical efficacy are not known. Facilitated by a new spindle poison diazonamide, we found that apoptosis induced by these agents requires death receptor 3 (DR3). Mitotic arrest by these agents induces lysosome-dependent secretion of the DR3 ligand, TL1A. Engagement of TL1A with DR3 stimulates the formation of FADD-containing and caspase-8-containing death-inducing signaling complex (DISC), which subsequently activates apoptosis in cells that express DR3. Expression of DR3 and TL1A correlates with the apoptotic response of human tumor xenograft models and human cancer cell lines to antimitotic drugs, providing further evidence that these drugs kill cancer cells through the DR3/TL1A-mediated pathway. These results suggest that TL1A and DR3 may hold promise to be used as biomarkers for predicting clinical response to antimitotic therapeutics. Nature Publishing Group UK 2018-03-01 2018-05 /pmc/articles/PMC5951888/ /pubmed/29497138 http://dx.doi.org/10.1038/s41422-018-0018-6 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Qi, Chen
Wang, Xin
Shen, Zhirong
Chen, She
Yu, Hong
Williams, Noelle
Wang, Gelin
Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells
title Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells
title_full Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells
title_fullStr Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells
title_full_unstemmed Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells
title_short Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells
title_sort anti-mitotic chemotherapeutics promote apoptosis through tl1a-activated death receptor 3 in cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951888/
https://www.ncbi.nlm.nih.gov/pubmed/29497138
http://dx.doi.org/10.1038/s41422-018-0018-6
work_keys_str_mv AT qichen antimitoticchemotherapeuticspromoteapoptosisthroughtl1aactivateddeathreceptor3incancercells
AT wangxin antimitoticchemotherapeuticspromoteapoptosisthroughtl1aactivateddeathreceptor3incancercells
AT shenzhirong antimitoticchemotherapeuticspromoteapoptosisthroughtl1aactivateddeathreceptor3incancercells
AT chenshe antimitoticchemotherapeuticspromoteapoptosisthroughtl1aactivateddeathreceptor3incancercells
AT yuhong antimitoticchemotherapeuticspromoteapoptosisthroughtl1aactivateddeathreceptor3incancercells
AT williamsnoelle antimitoticchemotherapeuticspromoteapoptosisthroughtl1aactivateddeathreceptor3incancercells
AT wanggelin antimitoticchemotherapeuticspromoteapoptosisthroughtl1aactivateddeathreceptor3incancercells